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The pharmacokinetics (PK) and pharmacodynamics (PD) of metronomic irinotecan have not been studied in cancer patients. The aim
of the study is to investigate the PK/PD profile of irinotecan/SN-38 administered by metronomic schedule. Twenty chemotherapy-
refractory or chemotherapy-resistant patients with metastatic colorectal carcinoma were enrolled. Irinotecan was infused
continuously as follows: irinotecan 1.4mgm
 2day
 1 (n¼7), 2.8mgm
 2day
 1 (n¼5) and 4.2mgm
 2day
 1 (n¼8). Drug levels
were examined by HPLC, whereas ELISAs and real-time RT-PCR were used, respectively, for the measurement of plasma levels and
gene expression in peripheral blood mononuclear cells of vascular endothelial growth factor/thrombospondin-1. Pharmacokinetic
analysis demonstrated that the steady-state levels (Css) of SN-38 were between 1 and 3.3ngml
 1. From a PD point of view, higher
thrombospondin-1 (TSP-1) plasma levels (153.4±30.1 and 130.4±9.2% at day 49 vs pretreatment values at 1.4 and
2.8mgm
 2day
 1 dose levels, respectively) and increased gene expression in PBMC were found during the metronomic irinotecan
infusion, especially at the lower doses. Four patients (20%) obtained a stable disease (median 3.9 months) despite progressing during
previous standard irinotecan schedule. Toxicities 4grade 1 were not observed. Metronomic irinotecan administration is very well
tolerated and induces an increase of gene expression and plasma concentration of TSP-1 at low plasma SN-38 concentrations.
British Journal of Cancer (2008) 98, 1312–1319. doi:10.1038/sj.bjc.6604311 www.bjcancer.com
Published online 25 March 2008
& 2008 Cancer Research UK
Keywords: metronomic chemotherapy; angiogenesis; irinotecan; colon cancer; clinical study; thrombospondin-1
                                                   
Chemotherapy administration using long-term, continuous and
low-dose schedule has been recently introduced in the therapy of
solid tumours. Colleoni and co-workers have used the metro-
nomic/antiangiogenic strategy, mainly based on the use of daily
oral cyclophosphamide (CTX) in combination with low-dose
methotrexate given 2 days/week, in clinical trials for the treatment
of metastatic breast cancer patients, and reported promising
clinical activity in the absence of serious adverse events (Colleoni
et al, 2002, 2006; Orlando et al, 2006a,b). Moreover, the low-
toxicity profile (Kerbel and Kamen, 2004) and the low costs (Bocci
et al, 2005b) of the metronomic CTX regimens enhanced the
quality of life of patients and suggested immediate potential use in
various clinical settings. Glode et al (2003) and Vogt and
co-workers (Vogt et al, 2003; Coras et al, 2004) studied a metronomic
chemotherapy schedule based on alkylating agents (CTX and
trofosfamide, respectively) in combination with drugs thought to
have some antiangiogenic effects (i.e., dexamethasone, rofecoxib
and pioglitazone), demonstrating efficacy as a salvage therapy in
the treatment of patients with hormone-refractory prostate
carcinoma (Glode et al, 2003) or palliative treatment of patients
with advanced malignant vascular tumours (Vogt et al, 2003) and
endemic Kaposi sarcoma (Coras et al, 2004). More recently, the
metronomic administration of CTX or vinblastine (Stempak et al,
2006) was studied in paediatric cancer patients, while temozolo-
mide (Baruchel et al, 2006; Stempak et al, 2006) was administered
in children with recurrent/refractory brain tumours without severe
toxicities and with positive results. Continuous oral thalidomide
and celecoxib with alternating oral etoposide and CTX have been
also studied in paediatric cancer patients (Kieran et al, 2005).
Garcia et al (2008) have recently reported encouraging phase II
trial results of metronomic cyclophosphamide, administered daily,
in combination with bevacizumab given every 2 weeks, for
treatment of recurrent ovarian cancer.
As stated above, preclinical and clinical experiences on
metronomic chemotherapy are so far almost mostly focused on
low-dose CTX; therefore, studies on other chemotherapeutic drugs
are urgently needed. Moreover, rational and less empirical
approaches to the clinical development of new metronomic
schedules could help setting a more rigorous standard into this
evolving and growing field of chemotherapy.
Drugs affecting pathological angiogenesis represent a new and
promising approach to metastatic colorectal cancer (mCRC), as
shown by the results of the bevacizumab-based phase III clinical
studies (Hurwitz et al, 2005). Further evaluations of antiangiogenic
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potential to improve prognosis and quality of life of patients with
mCRC. Over the last few years, the introduction of new
chemotherapeutic drugs such as irinotecan has resulted in
improved prognosis of patients with mCRC (Holen and Saltz,
2001). Despite abundant information about the pharmacology of
irinotecan (Di Paolo et al, 2006), and its active metabolite SN-38,
on cancer cells using different therapeutic approaches, no data are
currently available about clinical effects of metronomic irinotecan
administration.
Based on this background, we decided to perform a pharmaco-
kinetic/pharmacodynamic (PK/PD) study in 20 patients with
mCRC, heavily pretreated with both irinotecan- and oxaliplatin-
based chemotherapy, to investigate the (i) PK of metronomic
irinotecan/SN-38 at different dose levels; and (ii) changes in
antiangiogenic (thrombospondin-1 (TSP-1)) and proangiogenic
factors (vascular endothelial growth factor (VEGF)) during
treatments.
MATERIALS AND METHODS
Patient selection
The study was approved by the local ethics committee and
registered in the European Clinical Trial Database EudraCT
(http://eudract.emea.europa.eu; EudraCT registration number
2006-001045-34), and patients were informed of the investigational
nature of the study and provided their written informed consent.
Patients with a confirmed histological diagnosis of mCRC with no
operable disease were studied (Table 1). Other main eligibility
criteria included (1) previous chemotherapy with fluoropyrimi-
dines, oxaliplatin, irinotecan; (2) measurable disease progressing
during (refractory patients) or within 3 months (resistant patients)
from the end of the treatments; (3) age p75 years; (4) ECOG
performance status of p2; (5) adequate bone marrow, renal and
liver function (leukocyte count X3000mm
 3, platelet count
X100000mm
 3, serum creatinine p1.3mgdl
 1, serum bilirubin
p1.5mgdl
 1, AST and ALT p2.5 times normal values); (6) life
expectancy of more than 3 months. Exclusion criteria were as
follows: brain metastasis, symptomatic cardiac disease, recent
history of myocardial infarction, active infections and inflamma-
tory bowel disease.
Treatment schedule and doses
Irinotecan was administered as continuous i.v. infusion. Its
administration required the implant of a central venous catheter
and the use of an external programmable pump (Deltec CADD-
Plus, St Paul, MN, USA). Every week external volumetric pumps
were refilled with the weekly dose of irinotecan dissolved in NaCl
0.9%. Under these conditions, irinotecan is stable for extended
periods of time (Li and Koda, 2002). To define the optimal
metronomic dose of irinotecan, we calculated the weekly dose
intensity (DI) of irinotecan when administered with the schedule
proposed by Herben et al (1999) (39.4mgm
 2; irinotecan is given
3 out of 4 weeks continuously) that corresponded to a daily dose of
irinotecan of 5.6mgm
 2; therefore, we chose three different dose
levels of irinotecan, starting from a reduction of 75%, followed by
the 50 and 25% with respect to the calculated dose of
5.6mgm
 2day
 1 previously reported. The doses of irinotecan
administered by metronomic schedule for each group of patients
were as follows:
(1) 1.4mgm
 2day
 1 (DI¼9.8mgm
 2week
 1, number of
patients¼7)
(2) 2.8mgm
 2day
 1 (DI¼19.6mgm
 2week
 1, number of
patients¼5)
(3) 4.2mgm
 2day
 1 (DI¼29.4mgm
 2week
 1, number of
patients¼8)
Neither antiemetic premedication nor prophylactic treatment
with granulocyte colony-stimulating factor (G-CSF) was adminis-
tered. The patients continued the treatment until progression of
disease or patient’s consent withdrawal.
Clinical assessment, toxicity and response criteria
Pretreatment evaluation included history and physical examina-
tion, performance status assessment, complete blood cell with
differential and platelet counts, complete blood profile, tumour
markers, urinalysis, ECG, chest X-ray or computed tomography
scan, abdominal computed tomography scan and/or sonogram,
and any other appropriate diagnostic procedure to evaluate
metastatic sites. During treatment, a physical examination, a
complete blood cell count, blood profile, urinalysis and toxicity
evaluation were performed every week, immediately before pump
refilling. Sites of metastatic disease were radiologically
re-evaluated every 2 months, according to the RECIST criteria
(Therasse et al, 2000). A chest X-ray and/or an abdominal
sonogram were repeated at least every 6 months if there was no
evidence of lung or abdominal disease, respectively. Toxicities
were scored according to the standard NCI Common Terminology
Criteria for Adverse Events, version 3.0. Duration of responses was
calculated from the first day of treatment to the date of first
observation of progressive disease or last examination.
Table 1 Patient characteristics
n 20
Median age (years) (range) 71 (51–79)
Gender (male/female) 11/9
ECOG (0/1/2) 8/11/1
Primary tumour site (n)
Colon 16
Rectum 4
Metastatic sites (n)
Liver 16
Lungs 13
Peritoneum 4
Lymph nodes 3
Others 3
No. of metastatic sites (n)
Single 7
Multiple 13
Previous chemotherapy (%)
Irinotecan based 100
Fluoropyrimidine based 100
Oxaliplatin based 100
Cetuximab+irinotecan 35
No. of previous cancer treatments for advanced disease (%)
Two 55
More than two 45
Irinotecan dose (mgm
 2day
 1) (n)
1.4 7
2.8 5
4.2 8
Median CEA (ngml
 1) (range) 62.3 (0.8–5104)
Median body surface area (m
2) (range) 1.77 (1.64–2)
TSP-1 pretreatment levels (ngml
 1) (mean±s.d.) 213.9±110.08
VEGF pretreatment levels (pgml
 1) (mean±s.d.) 158.6±83.5
CEA, carcino-embryonic antigen; ECOG, eastern cooperative oncology group;
n¼no. of patients; TSP-1¼thrombospondin-1; VEGF¼vascular endothelial growth
factor.
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SN-38 glucuronide
The PK analysis of irinotecan and its main metabolites SN-38 and
SN-38 glucuronide (SN-38glu) was performed as previously
described (Masi et al, 2004) with minor modifications. Blood
samples (4ml each) for drug assays were taken from an indwelling
i.v. cannula placed in an antecubital vein at baseline, 30min, 1h,
and at days 7, 14, 21, 28, 35, 42, 49, 56 and 63 after the beginning of
irinotecan i.v. infusion; at day 63, at the end of the infusion and
before refilling the pump, the blood sampling was performed after
30min, 2 and 6h. Blood was collected in heparinised tubes
(Vacutainer tubes; Becton Dickinson Vacutainer System) and then
centrifuged (10min, 4000r.p.m., 41C) to separate plasma, which
was stored at  201C and assayed within 1 week. Briefly,
concentration of irinotecan and SN-38 was evaluated after
extraction of 1ml of plasma with methanol containing 0.1% HCl
(10N); the samples were then centrifuged and the clear super-
natant was evaporated to dryness under nitrogen flow in a
thermostated bath at 451C. The resulting pellet was reconstituted
in methanol acidified with 0.1% HCl (10N) and eluted through a
mBondapack C18 stationary phase column (300 3.9mm, 10mm;
Waters, Milford, MA, USA) by KH2PO4 (0.1M)/acetonitrile (60:40,
v/v; pH 6.0) containing sodium heptansulphonate 3mmoll
 1. The
chromatographic system LC Module I Plus (Waters) was equipped
with a Model 474 scanning fluorescence detector with excitation
and emission wavelengths set at 375 and 525nm, respectively. Data
analysis was performed using Millennium 2.1 software (Waters).
The SN-38glu plasma concentration was measured after incubation
of plasma samples with b-glucuronidase (10UIml
 1 of plasma) at
371C for 2h before extraction. The difference between peak areas
corresponding to SN-38 in b-glucuronidase-treated vs untreated
samples corresponded to the plasma levels of SN-38glu. Standard
calibration curves were generated on each day of analysis by
adding irinotecan and SN-38 to 1ml of blank plasma obtained
from healthy donors, resulting in final concentrations that ranged
from 12500 to 0.8ngml
 1 and 2500 to 0.16ngml
 1 for irinotecan
and SN-38, respectively. The range of linearity of the HPLC
method was from 0.8 to 12500ngml
 1 for irinotecan and 2500 to
0.16ngml
 1 for SN-38.
Individual plasma concentration profiles of irinotecan and its
catabolites were fitted according to a two-compartment open
model by means of the WinNonlin 5.1 computer software
(Pharsight Corporation, Mountain View, CA, USA) The AUC of
irinotecan (CPT-11), SN-38 and SN-38glu from 0 to 63.25 days was
calculated by the log-linear trapezoidal method until the last
sampling time. Peak plasma concentration (Cmax) was obtained by
visual inspection of the concentration vs time profile of irinotecan
and metabolites, whereas steady-state concentrations (Css) were
calculated as mean values of plasma levels at days 7, 14, 21, 28, 35,
42, 49, 56 and 63 of infusion. Finally, the clearance of irinotecan
(CL) was determined as the infusion rate of the drug divided by its
Css value. The relative extent of metabolic conversion (REC) of
irinotecan was calculated as AUCSN-38/AUCCPT-11, whereas the
drug metabolic ratio (MR) was obtained as (AUCSN-38þAUCSN-
38glu)/AUCCPT-11. The glucuronidation ratio (GR) was calculated as
the AUCSN-38glu/AUCSN-38 to obtain an indirect estimate of the
activity of glucuronidation of the active metabolite SN-38, and the
biliary index (BI) was evaluated as (AUCCPT-11) (AUCSN-38/
AUCSN-38glu).
Assessment of human VEGF and TSP-1 gene expression
and plasma levels
Before drug administration and at days 7, 14, 21, 28, 35, 42, 49, 56
and 63, 10ml of blood was drawn from the antecubital vein of
patients. Peripheral blood mononuclear cells (PBMC) were
collected as described (Bocci et al, 2006) and the cell suspension
was centrifuged at 1000r.p.m. for 10min and washed with PBS; the
resulting pellet was immediately frozen in liquid nitrogen and
stored at  801C. Briefly, RNA (1mg) was reverse transcribed (Bocci
et al, 2005a) and the resulting cDNA was diluted (2:3) and then
amplified by QRT-PCR with the Applied Biosystems 7900HT
sequence detection system. Vascular endothelial growth factor-
and TSP-1-validated primers were purchased from Applied
Biosystems (Assay ID Hs00170236_m1 and Hs00173626_m1,
respectively). The PCR thermal cycling conditions and optimisa-
tion of primer concentrations were followed as per the manufac-
turer’s instructions. Amplifications were normalised to GAPDH
and the quantitation of gene expression was performed using the
DDCt calculation; the amounts of VEGF and TSP-1, normalised to
the endogenous control and relative to the calibrator (PBMC
sample at day 0), are given as 2 DDCt. The data are presented as the
percentage of 2 DDCt before the beginning of irinotecan infusion.
Plasma samples obtained at the same days of PBMC collection
were assessed for TSP-1 and VEGF levels using the commercially
available ELISA and EIA kits. Each sample was assayed for human
VEGF and TSP-1 concentrations by the ELISA Kit Quantikine
s
(R&D Systems, USA) and by the ChemiKinet Human TSP-1 EIA
Kit (Chemicon, Temecula, CA, USA), respectively. Measurements
were performed by the microplate reader Multiskan Spectrum
(Thermo Labsystems, Milan, Italy) set to 450nm (with a
wavelength correction set to 540nm) for the VEGF kit and
490nm for TSP-1 kit. The data are presented as the percentage of
the VEGF and TSP-1 plasma levels at day 0.
Statistical analysis
Since the study was exploratory in nature, no statistical hypothesis
testing has been performed. Moreover, the sample size (20
patients) has been judged to be adequate based on the suggestions
of the entropy-based approach to sample size in translational
clinical trials (Piantadosi, 2005). The analysis by ANOVA, followed
by the Student–Newman–Keuls test, was used to assess the
statistical differences of data. P-values lower than 0.05 were
considered significant. Statistical analyses were performed using
the GraphPad Prism software package version 4.0 (GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
Patients and toxicity
As outlined in Table 1, 20 patients with advanced mCRC entered
the study. Median age was 71 years (range, 51–79 years), ECOG
performance status was 0–1 in 18 patients and 2 in one. As
reported, the entire study population was heavily pretreated and
irinotecan refractory or resistant. Of note, 35% of patients had also
received a cetuximab-based therapy. Overall, 188 weeks of
irinotecan were administered by metronomic schedule with a
median of 9 weeks per patient (range, 2–20 weeks). The end of
treatment was due to disease progression in all patients.
All patients were assessable for toxicities. Toxicities were very
uncommon. In particular, we did not observe toxicities higher than
grade 1. Three (15%) and five patients (25%) experienced,
respectively, a transient grade 1 diarrhoea and nausea, resolved
without interrupting the treatment. No haematological toxicities
were observed.
Antitumour activity and survival
All 20 patients were assessable for response to treatment. Four
patients treated at 1.4mgm
 2day
 1 (1 patient), 2.4mgm
 2day
 1
(2 patients) and 4.2mgm
 2day
 1 (1 patient) obtained a stabilisa-
tion of disease that lasted a median period of 3.9 months (range,
3–5 months). In the remaining 16 patients, disease progression
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up of 20 months, median progression-free survival (PFS) was 2.07
months (95% CI: 1.99–2.14) and median overall survival (OS) was
8.4 months (95% CI: 5.1–11.7); curves estimated by the Kaplan–
Meier method from the first day of treatment are reported in
Figure 1.
Pharmacokinetics of metronomic irinotecan, SN-38 and
SN-38glu
Main PK parameters of irinotecan and its metabolites are reported
in Table 2, whereas the plasma profiles of irinotecan, SN-38 and
SN-38glu at the different infusion schedules are shown in Figure
2A–C, respectively. Pharmacokinetic analysis demonstrated that
the Css of irinotecan 1.4, 2.8 and 4.2mgm
 2day
 1 were
143.1±56.8, 231.6±101.4 and 390±171ngml
 1, respectively,
whereas those of SN-38 were 1.00±0.52, 2.29±0.87 and
3.33±0.96ngml
 1, respectively, and resulted statistically different
among them (Po0.05). Moreover, the Css of SN-38glu were, as
expected, higher than the ones of SN-38. Pharmacokinetic analysis
of irinotecan showed an increased metabolism of the parent drug
into the active metabolite SN-38 when higher doses were
administered (Figure 2B). As expected, irinotecan AUC value was
higher at the 4.2 dose with respect to the 2.8 and 1.4 doses, even
though it was not statistically significant, whereas mean AUC value
of SN-38 was significantly lower at 1.4 dose than at 2.8 and 4.2
doses (Po0.05) (Table 2). The comparison of PK of irinotecan at
different doses did not reveal any significant difference among
Cmax and t1/2b values (Table 2). Instead, significant differences
were found for Cmax values of SN-38 and SN-38glu at different
irinotecan doses. Further analysis demonstrated that the higher
doses led to an increase in BI, REC and MR values, even if only the
increase of BI was statistically significant (Po0.05). Instead, GR
value did not significantly increase after administration of higher
doses of irinotecan (Table 2).
Changes in TSP-1 and VEGF plasma and gene expression
in PBMC
To compare the variations of plasma TSP-1 and VEGF before and
during the metronomic treatments, graphs were drawn to show the
concentrations as a percentage of the concentration at day 0 of
individual patients before the starting of irinotecan infusion.
Figure 3A shows that TSP-1 levels markedly increased in treated
patients and remain consistently higher for more than 8 weeks.
Table 2 Pharmacokinetic parameters of irinotecan, SN-38 and SN-38glu at the doses of irinotecan 1.4, 2.8 and 4.2mgm
 2day
 1 in 20 patients
Mean±s.d.
1.4mgm
 2day
 1 (n¼7) 2.8mgm
 2day
 1 (n¼5) 4.2mgm
 2day
 1 (n¼8)
Irinotecan
AUC (dayngml
 1) 8714.7±1564.3 13877.7±3035.2 23051.6±5002.3
CL (mlday
 1m
 2) 154.32±28.4 170.31±44.2 146.11±25.3
t1/2b (h) 15.9±5.1 20.2±6.2 14.6±3.2
Cmax (ngml
 1) 277.6±125.3 382.9±261.8 484.1±243.1
Css (ngml
 1) 143.1±56.8 231.6±101.4 390.0±171.0
a,b
Tmax (day) 35 35 28
SN-38
AUC (dayngml
 1) 59.43±7.47 136.21±10.61
c 200.48±12.26
a,b
t1/2b (h) 18.9±4.3 22.8±6.7 19.9±7.2
Cmax (ngml
 1) 1.62±0.45 2.61±1.07 4.03±2.19
a
Css (ngml
 1) 1.00±0.52 2.29±0.87
c 3.33±0.96
a,b
Tmax (day) 42 35 35
SN-38glu
AUC (dayngml
 1) 100.94±8.82 268.86±14.52
c 430.10±24.34
a,b
t1/2b (h) 22.31±5.1 17.4±5.6 21.33±6.8
Cmax (ngml
 1) 2.24±0.58 5.59±1.91
c 8.45±2.54
a,b
Css (ngml
 1) 1.63±0.53 4.42±1.98
c 7.20±1.59
a,b
Tmax (day) 49 42 42
BI 5130.1±745 7030.7±537
c 10744.9±892
a,b
REC 0.0068±0.0048 0.0098±0.0035 0.0087±0.0025
MR 0.0184±0.0104 0.0292±0.0183 0.0274±0.0116
GR 1.698±0.206 1.974±0.402 2.145±0.623
AUC¼area under the time/concentration curve; BI¼biliary index; Cmax¼maximal plasma concentration; Css¼steady-state concentration; GR¼glucuronidation ratio;
MR¼metabolic ratio; REC¼relative extent of conversion; SN-38glu¼SN-38 glucuronide; t1/2b¼terminal half-life; Tmax¼time to peak.
aPo0.05 4.2 vs 1.4.
bPo0.05 4.2 vs 2.8.
cPo0.05 2.8 vs 1.4.
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Figure 1 Actuarial PFS and OS curves calculated by the Kaplan–Meier
method from the first day of metronomic irinotecan chemotherapy.
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the three dose levels: the average TSP-1 increase was higher at the
lower doses of 1.4 and 2.8mgm
 2day
 1 (Figure 3A) reaching
maximum increments at day 49 of 153.4±30.9 and 130.5±9.3%,
respectively, vs 100% of day 0. In contrast, TSP-1 concentrations in
patients treated with CPT-11 at 4.2mgm
 2day
 1 returned to the
baseline values after an initial increase (Figure 3A). Figure 3B
shows the results of the different profiles of VEGF plasma levels in
the treated patients. Mean plasma VEGF levels, although with a
high variability, increased in the first 3 weeks of treatment,
whereas after day 28 they returned to baseline levels (Figure 3B).
However, differences were noticed among the three dose levels: at
the lowest dose (1.4mgm
 2day
 1) VEGF concentrations de-
creased (at day 56, 77.9±18 vs 100% of day 0), whereas at the
highest dose (4.2mgm
 2day
 1) they increased (at day 56,
126.3±67 vs 100% of day 0) during the CPT-11 infusion.
Interestingly, only at lower metronomic doses, there was a
simultaneous increase in TSP-1 levels and a decrease of VEGF
concentrations, which would suggest a shift to an antiangiogenic
state.
Figure 3C and D shows TSP-1 and VEGF gene expression
profiles in PBMC, a normal cell compartment. Differences were
found in TSP-1 gene expression among the three dose levels.
Indeed, the irinotecan 1.4mgm
 2day
 1 determined a marked
increase in TSP-1 gene expression in PBMC at least until day 42
(222.4±106.9 vs 100% of day 0), whereas at the other doses a
marked increase was seen only after day 35 (Figure 3C). In
contrast, VEGF expression profile in PBMC was similar to baseline,
with the exception of an initial increase (at day 14, 172.6±73.3 vs
100% of day 0 for 1.4mgm
 2day
 1 dose).
DISCUSSION
The present study described, for the first time, the PK of
metronomic irinotecan and demonstrated a marked increase in
TSP-1 plasma concentrations and gene expression (already at
lower irinotecan dose levels), suggesting a possible use of this PD
marker in irinotecan-based metronomic treatment strategies.
Moreover, low-dose metronomic irinotecan was not toxic and
potentially active in heavily pretreated, refractory or resistant
population of mCRC patients.
Based on promising antiangiogenic and antitumour preclinical
results (Bocci et al, 2007), we decided to test the metronomic
irinotecan schedule in the clinic, specifically in patients with
mCRC resistant to irinotecan standard doses. The ‘ethical
condition’ to evaluate the clinical effect of an irinotecan
metronomic treatment in this patient population depended on
the fact that there was no evidence that a third/fourth line of
chemotherapy could produce an improvement in terms of clinical
benefit or efficacy in patients with mCRC already treated with both
oxaliplatin- and irinotecan-based chemotherapy. The results of
several phase II clinical studies showed that a third/fourth line of
fluoropyrimidine-based chemotherapy in this setting of patients
generally produces a poor response rate (around or less than 10%),
with a median PFS between 2 and 3 months and with a median OS
of approximately 6–9 months (Chong et al, 2005; McCollum et al,
2006; Scartozzi et al, 2006). Besides the weak antitumour activity,
these treatments are limited by a substantial toxicity Xgrade 3
(NCI scale) reported in about 10–15% of all patients. The role of
the targeted therapy in these setting of patients has also been
evaluated. Chen et al (2006) have recently published the results of a
large multicentre trial of bevacizumab in combination with
5-fluorouracil/leucovorin in patients with mCRC pretreated with
both oxaliplatin- and irinotecan-based chemotherapy. The results
have shown a response rate of 4%, a median PFS of 3.5 months and
a median OS of 9 months. Of note, adverse events Xgrade 3 were
reported in 47% of all treated patients.
More promising results seem to come from the use of the
monoclonal antibodies against the epidermal growth factor
receptor cetuximab and panitumumab in this setting of patients.
Jonker et al (2007) have evaluated, in a phase III clinical study, the
role of cetuximab in patients with mCRC pretreated with an
oxaliplatin- and irinotecan-based chemotherapy, showing an
improvement in terms of OS of cetuximab plus best supportive
care (BSC) respect to BSC alone (median OS of 6.1 vs 4.6 months,
P¼0.0046). Van Cutsem et al (2007) in a similar setting of patients
have compared panitumumab plus BSC to BSC alone, showing that
panitumumab prolonged the PFS (HR: 0.54; 95% CI: 0.44–0.66,
Po0.0001), with no difference in terms of OS. Despite the
promising results, some issues could limit the use of these
therapies in this setting of patients, such as the low impact on
survival, the high cost of the drugs and the significant higher rate
of grade 3–4 adverse events with respect to BSC. Thus, the study of
metronomic chemotherapy could be of interest in heavily
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spretreated mCRC. A recent study has evaluated the role of a
combination metronomic treatment with CTX, vinblastine and
rofecoxib in patients with advanced tumours, in which 13 patients
with diagnosis of mCRC were included. One patient had a partial
response, while another patient had a stable disease; the time to
progression of these patients was 12 and 7 months, respectively
(Young et al, 2006). These results suggest a potential anti-
tumour effect of the metronomic approach in patients with
mCRC.
One of the major concerns regarding the clinical application of
metronomic chemotherapy relates to the dosing levels and the
frequency of administration of the chemotherapeutic drugs. This
important issue has generated confusion regarding the term
‘metronomic’ that has been sometimes associated with a simple,
small reduction of a standard dose. Moreover, among the
published trials, the dose for the metronomic chemotherapy is
often arbitrarily chosen (e.g., the ‘classic’ fixed dose of 50mgday
 1
of CTX simply corresponds to a single tablet of the commercially
available medicament) and no further efforts have been made to
define the best dose. In our study, we evaluated three different
dose levels of metronomic irinotecan that was infused continu-
ously without breaks, starting from a reduction of 75% of the
maximum tolerable dose of irinotecan when infused continuously
more than 21 days every 28 days reported by Herben et al (1999).
Moreover, we thoroughly investigated the changes in TSP-1 and
VEGF expression/secretion in accessible compartments in meta-
static patients such as peripheral mononuclear cells and plasma to
confirm our preclinical data and find indexes of biological activity
of the CPT-11 metronomic treatment.
Although our study was not comparative, the results show that
the irinotecan metronomic chemotherapy produces clinical results
such as those observed with other schedules of third/fourth line of
treatment in patients with a diagnosis of metastatic colorectal
carcinoma, both in terms of median PFS and median OS.
Furthermore, our results were accompanied by a total absence of
toxicity and in a heavily pretreated, irinotecan-resistant population
with progressive disease. Moreover, G-CSF was not administered
to patients receiving metronomic irinotecan chemotherapy and as
such this could have an advantage, not only in terms of cost but
also in terms of avoiding the possibility that the exogenous G-CSF
might promote angiogenesis by mobilising circulating endothelial
progenitor cells (CEPs) (Natori et al, 2002; Shaked and Kerbel,
2007). Our results suggest that metronomic irinotecan chemo-
therapy could work through a mechanism of action that is not related
to the direct cytotoxic effect on tumour cells but rather through an
antiangiogenic activity targeting proliferating endothelial cells as
shown in the preclinical setting. Indeed, higher TSP-1 plasma
levels were found during the metronomic irinotecan infusion when
compared to the baseline values in single patients as well as the
increased gene expression in the PBMC compartment, especially at
the lower irinotecan doses. These findings clinically confirmed that
low-dose CPT-11 inhibits angiogenesis, in part, by upregulating
TSP-1 in tumour endothelial (Bocci et al, 2003), or tumour and
tumour-associated stromal cells (Hamano et al, 2004), promoting
endothelial cell apoptosis (de Castro Junior et al, 2006) and
suppressing the mobilisation of circulating endothelial progenitors
(Shaked et al, 2005). This linkage between PD parameters and dose
levels could open a promising area of clinical investigation on
surrogate markers for the activity of the metronomic chemo-
therapy approach. Indeed, a previous attempt to monitor putative
surrogate markers such as VEGF, endostatin and TSP-1 plasma
levels during metronomic CTX revealed a high degree of variability
and no statistically significant relationships between these markers
and disease progression or maintenance of stable disease in
paediatric patients (Stempak et al, 2006). However, the hetero-
geneous patient population, the drugs that were involved and the
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slack of a preclinical investigation of the doses that were used, and
combination of drugs used all could have affected the outcome of
the results. Colleoni et al (2002) described a reduction in serum
VEGF of both responders and non-responders in breast cancer
metastatic patients treated with metronomic CTX. In our study,
the individual plasma VEGF concentrations of patients initially
increased when compared to the baseline values in the first 3 weeks
and then at lower doses constantly decreased. Despite the presence
of a high variability, VEGF plasma levels may reflect both the
initial elevated hypoxia of tumour tissue caused by the antiangio-
genic therapy, as previously shown (Bocci et al, 2004; Motzer et al,
2006), and the low rate of VEGF secretion by tumour or tumour-
associated stromal cells due to the long-term therapy (Colleoni
et al, 2002).
This PK/PD study underlines the importance to conduct further
comparative studies with BSC or bevacizumab to establish the
feasibility of metronomic irinotecan approach. Moreover, this
suggests further clinical steps that might be explored such as the
administration of rubitecan, an oral camptothecin (Clark, 2006), or
combination studies with other low-dose oral chemotherapeutic
drugs already approved for colorectal cancer such as UFT (Munoz
et al, 2006) or capecitabine. In addition, combination of a targeted
antiangiogenic drug such as bevacizumab with metronomic
irinotecan therapy might also be considered in patients not
previously treated with this drug since such combinations show
much greater antitumour efficacy compared to metronomic
chemotherapy alone or the antiangiogenic drug alone (Klement
et al, 2000; Kerbel and Kamen, 2004; Pietras and Hanahan, 2005).
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